Last reviewed · How we verify
A Phase 1, Randomized, Investigator- and Participant-Blinded, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Characterize the Safety, Tolerability, and Pharmacokinetics of LY4515100 in Healthy Participants
The main purpose of this study is to assess the safety and tolerability of LY4515100 when given orally to healthy participants. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will last up to 30 days and will include six overnight stays.
Details
| Lead sponsor | Eli Lilly and Company |
|---|---|
| Phase | Phase 1 |
| Status | RECRUITING |
| Enrolment | 40 |
| Start date | 2026-01-15 |
| Completion | 2026-07 |
Conditions
- Healthy
Interventions
- LY4515100 via SAD
- LY4515100 via MAD
Primary outcomes
- Number of participants with one or more serious adverse event(s) (SAEs) of LY4515100 — Day 1 up to Day 30
SAEs of LY4515100
Countries
United States